Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
Identifieur interne : 003939 ( Main/Exploration ); précédent : 003938; suivant : 003940Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
Auteurs : Paolo Lamberti [Italie] ; Stefano Zoccolella [Italie] ; Giovanni Iliceto [Italie] ; Elio Armenise [Italie] ; Angela Fraddosio [Italie] ; Michele De Mari [Italie] ; Paolo Livrea [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-01.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), COMT inhibitors, Case-Control Studies, Catechols (pharmacology), Catechols (therapeutic use), Chromatography, High Pressure Liquid (methods), Drug Therapy, Combination, Female, Folic Acid (blood), Homocystein, Homocysteine (blood), Human, Humans, Levodopa, Levodopa (pharmacology), Levodopa (therapeutic use), Linear Models, Male, Middle Aged, Nervous system diseases, Nitriles, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Vitamin B 12 (blood), homocysteine, levodopa.
- MESH :
- chemical , blood : Folic Acid, Homocysteine, Vitamin B 12.
- chemical , pharmacology : Antiparkinson Agents, Catechols, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Catechols, Levodopa.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- methods : Chromatography, High Pressure Liquid.
- Aged, Case-Control Studies, Drug Therapy, Combination, Female, Humans, Linear Models, Male, Middle Aged, Nitriles.
Abstract
Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O‐methylation of levodopa catalyzed by catechol‐O‐methyltransferase (COMT) that produces S‐adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT‐I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT‐I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT‐I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa‐treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT‐I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT‐I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT‐I effectively reduces HHcy. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20261
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002A07
- to stream Istex, to step Curation: 002A07
- to stream Istex, to step Checkpoint: 002349
- to stream PubMed, to step Corpus: 003267
- to stream PubMed, to step Curation: 003267
- to stream PubMed, to step Checkpoint: 003151
- to stream Ncbi, to step Merge: 001021
- to stream Ncbi, to step Curation: 001021
- to stream Ncbi, to step Checkpoint: 001021
- to stream Main, to step Merge: 005026
- to stream PascalFrancis, to step Corpus: 001F44
- to stream PascalFrancis, to step Curation: 000D77
- to stream PascalFrancis, to step Checkpoint: 001E65
- to stream Main, to step Merge: 005343
- to stream Main, to step Curation: 003939
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients</title><author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name></author><author><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name></author><author><name sortKey="Iliceto, Giovanni" sort="Iliceto, Giovanni" uniqKey="Iliceto G" first="Giovanni" last="Iliceto">Giovanni Iliceto</name></author><author><name sortKey="Armenise, Elio" sort="Armenise, Elio" uniqKey="Armenise E" first="Elio" last="Armenise">Elio Armenise</name></author><author><name sortKey="Fraddosio, Angela" sort="Fraddosio, Angela" uniqKey="Fraddosio A" first="Angela" last="Fraddosio">Angela Fraddosio</name></author><author><name sortKey="De Mari, Michele" sort="De Mari, Michele" uniqKey="De Mari M" first="Michele" last="De Mari">Michele De Mari</name></author><author><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:059344931BC5E86B701FB0820B8FB0F10271CDBE</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20261</idno><idno type="url">https://api.istex.fr/document/059344931BC5E86B701FB0820B8FB0F10271CDBE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A07</idno><idno type="wicri:Area/Istex/Curation">002A07</idno><idno type="wicri:Area/Istex/Checkpoint">002349</idno><idno type="wicri:doubleKey">0885-3185:2005:Lamberti P:effects:of:levodopa</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15390046</idno><idno type="wicri:Area/PubMed/Corpus">003267</idno><idno type="wicri:Area/PubMed/Curation">003267</idno><idno type="wicri:Area/PubMed/Checkpoint">003151</idno><idno type="wicri:Area/Ncbi/Merge">001021</idno><idno type="wicri:Area/Ncbi/Curation">001021</idno><idno type="wicri:Area/Ncbi/Checkpoint">001021</idno><idno type="wicri:doubleKey">0885-3185:2005:Lamberti P:effects:of:levodopa</idno><idno type="wicri:Area/Main/Merge">005026</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0173268</idno><idno type="wicri:Area/PascalFrancis/Corpus">001F44</idno><idno type="wicri:Area/PascalFrancis/Curation">000D77</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001E65</idno><idno type="wicri:doubleKey">0885-3185:2005:Lamberti P:effects:of:levodopa</idno><idno type="wicri:Area/Main/Merge">005343</idno><idno type="wicri:Area/Main/Curation">003939</idno><idno type="wicri:Area/Main/Exploration">003939</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients</title><author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Iliceto, Giovanni" sort="Iliceto, Giovanni" uniqKey="Iliceto G" first="Giovanni" last="Iliceto">Giovanni Iliceto</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Armenise, Elio" sort="Armenise, Elio" uniqKey="Armenise E" first="Elio" last="Armenise">Elio Armenise</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Internal Medicine and Public Health‐Hygiene Section, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Fraddosio, Angela" sort="Fraddosio, Angela" uniqKey="Fraddosio A" first="Angela" last="Fraddosio">Angela Fraddosio</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="De Mari, Michele" sort="De Mari, Michele" uniqKey="De Mari M" first="Michele" last="De Mari">Michele De Mari</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bari, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-01">2005-01</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="72">72</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">059344931BC5E86B701FB0820B8FB0F10271CDBE</idno><idno type="DOI">10.1002/mds.20261</idno><idno type="ArticleID">MDS20261</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>COMT inhibitors</term><term>Case-Control Studies</term><term>Catechols (pharmacology)</term><term>Catechols (therapeutic use)</term><term>Chromatography, High Pressure Liquid (methods)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Folic Acid (blood)</term><term>Homocystein</term><term>Homocysteine (blood)</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Linear Models</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Nitriles</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Vitamin B 12 (blood)</term><term>homocysteine</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Folic Acid</term><term>Homocysteine</term><term>Vitamin B 12</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chromatography, High Pressure Liquid</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Linear Models</term><term>Male</term><term>Middle Aged</term><term>Nitriles</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Homocystéine</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O‐methylation of levodopa catalyzed by catechol‐O‐methyltransferase (COMT) that produces S‐adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT‐I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT‐I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT‐I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa‐treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT‐I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT‐I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT‐I effectively reduces HHcy. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name></noRegion><name sortKey="Armenise, Elio" sort="Armenise, Elio" uniqKey="Armenise E" first="Elio" last="Armenise">Elio Armenise</name><name sortKey="De Mari, Michele" sort="De Mari, Michele" uniqKey="De Mari M" first="Michele" last="De Mari">Michele De Mari</name><name sortKey="Fraddosio, Angela" sort="Fraddosio, Angela" uniqKey="Fraddosio A" first="Angela" last="Fraddosio">Angela Fraddosio</name><name sortKey="Iliceto, Giovanni" sort="Iliceto, Giovanni" uniqKey="Iliceto G" first="Giovanni" last="Iliceto">Giovanni Iliceto</name><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:059344931BC5E86B701FB0820B8FB0F10271CDBE
|texte= Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
}}
| This area was generated with Dilib version V0.6.23. |  |